Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Makes Its Move, Buys Abbott Generics In Tax Inversion Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

Mylan will buy Abbott’s non-U.S. developed markets specialty and branded generics business in a stock transaction valued at around $5.3 billion, a deal that will allow it to redomicile in the Netherlands.

You may also be interested in...



Emerging Markets Earnings: Abbott Laboratories Casts Fortune Abroad

Emerging markets now account for nearly half of Abbott Laboratories sales – a figure set to grow through regional focus and acquisitions, leading Chicago-based CEO Miles White and other executives to skip over vast portions of the globe in the third quarter earnings call.

Emerging Markets Earnings: Abbott Laboratories Casts Fortune Abroad

Emerging markets now account for nearly half of Abbott Laboratories sales – a figure set to grow through regional focus and acquisitions, leading Chicago-based CEO Miles White and other executives to skip over vast portions of the globe in the third quarter earnings call.

Mylan Increases Injectable Presence, But In Declining Market

The generics company added to its arsenal of injectable drugs by acquiring rights to Aspen’s DVT treatment Arixtra, but the anticoagulant faces tough competition from oral entrants.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS077432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel